Clinical Trials Browser

Phase 2 × Neurofibroma, Plexiform × trametinib × Clear all

NCT03363217 2026-04-24

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Phase 2 Active not recruiting

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03741101 2024-04-11

plexifpc

Phase 2 Unknown

Neurofibromatosis 1, Neurofibroma, Plexiform